Navigation Links
Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
Date:12/10/2007

erability of XL019 when administered orally once daily for 21 days in 28-day cycles. Secondary objectives include evaluation of the pharmacokinetics and pharmacodynamics of XL019, and to evaluate response using the International Working Group for MF consensus response criteria.

Results To-Date

Data (unaudited) from cohort 1 (100mg), cohort 2 (200mg) and cohort 3 (300mg) were presented today and the key findings by investigators include:

-- Preliminary clinical activity observed in most subjects, including:

- Reduction in spleen size of 33 to 100% in five of six patients

evaluated

- Reduction in erythropoietin-independent colony formation of up to

39% and up to 100% in two patients evaluated

-- Relief of constitutional symptoms, including pruritus, fatigue, back

pain and abdominal fullness

-- Reduction in the number of cells with the JAK2 V617F mutation (allele

burden)

-- Correlation between XL019 exposure and decreases in phosphorylation of

STAT, a marker for JAK activity.

-- XL019 was generally well tolerated.

- Adverse events included Grade 1 nausea, headaches, equilibrium

imbalance, dizziness, chest discomfort, visual disturbances, fatigue

and hypertension.

- Grade 2 AEs of lightheadedness and decreased sensation in soles and

one serious adverse event of confusion in a patient with baseline

history of dementia were also observed.

-- No evidence of myelosuppression

The maximum tolerated dose has not been reached. The phase 1 dose escalating clinical trial continues.

About JAK2 and XL019

JAK kinases are activated by cytokines and growth factor receptors and phosphorylate members of the STAT family of inducible transcription factors. JAK2 plays a pivotal role in the cellular response to growth factors that drive blood cell expansion, including erythrop
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 On Thursday, ... 0.52%, the Dow Jones Industrial Average finished the day 0.42% ... down 0.41%. The losses were broad based as eight out ... 500 Health Care Sector Index ended the day at 711.88, ... last one month. Investor-Edge has initiated coverage on the following ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... -- Integrated Silicon Solution, Inc. (Nasdaq: ISSI ... solutions, today announced that it will host its earnings ... a.m. Pacific Time (10:00 a.m. Eastern Time) to discuss ... quarter ended June 30, 2014. To access ... a.m. Pacific time on July 24, 2014.  The participant ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Inc. (Nasdaq: BIOD ) will issue its third ...  Following the release of the company,s financial results, Biodel,s senior ... and provide an update on the company,s progress.August 4, 2011 ... be distributed4:15 pm EDT: , Conference call participants should dial:+1 ...
... Reportlinker.com announces that a new market research ... Insulin- Western Europe ... package contains 14 insulin market analyses from ... Denmark, Finland, France, Germany, Ireland, Italy, the ...
Cached Medicine Technology:Insulin- Western Europe 2
(Date:7/11/2014)... Riverside Health System became the first provider of Community- ... and now, in partnership with Williamsburg Landing, will offer its ... Newport News region. , Also known as life care at ... adults who wish to remain in their homes but want ... services as well as control over the cost of long-term ...
(Date:7/11/2014)... scientists have been trying to unravel mechanisms that guide ... that generate all blood cells including our immune system. ... because they can only be found in the bone ... a culture dish. Now a group of scientists from ... (Technische Universitt Dresden) was able to generate a mouse ...
(Date:7/11/2014)... 2014 WWTrek Human Outreach Project ... Community in Tanzania. Opened in 2012, the KKC is now ... cows. HOP Founder, Dean Cardinale, started the KKC to create ... orphaned children he encountered while running treks on Tanzania's Mount ... who have all made astounding progress in school over the ...
(Date:7/11/2014)... Francisco shows that an "expressive therapy" group intervention ... with HIV disclose their health status and improves ... quality of their relationships., "Medication alone is totally ... Machtinger, MD, director of the Women,s HIV Program ... are on effective antiretroviral therapy but far too ...
(Date:7/11/2014)... 2014 Recently, iFitDress.com, a leading online ... has released its new collection of evening dresses ... has announced that all these beautiful items are provided ... of the special offer is July 22. , ... pay close attention to customer satisfaction. On the company’s ...
Breaking Medicine News(10 mins):Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Opening-up the stem cell niche 2Health News:Human Outreach Project Sees Incredible Progress in the Kilimanjaro Kids Community 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2
... Windows Vista, Adobe Flash 10 and high-availability failover support. , ... ... today announced the release of the latest version of the industry ... of CoolSign further builds on its existing enterprise-based, robust feature set, ...
... 2009 As Zimbabwe continues to confront a,cholera ... a new,World Vision project supported by the Procter ... Drinking Water Program is underway, providing Zimbabweans with ... families and their,communities. , ...
... a limited edition beauty bag filled with products as ... Wash. and NEW YORK, Feb. 24 Beauty.com, Inc., ... DSCM ), announces Shoshanna Gruss as their ... program. Beginning February 25th, the exclusive Shoshanna-designed beauty case ...
... Them Crazy While They Work...30,000+ Dentists Converge in Chicago ... being issued by the Chicago Dental Society:Who: The ... members to find out some wacky, unusual, and just ... their chair.As we countdown to CDS,s annual Midwinter Meeting, ...
... dental techniques, , , TUESDAY, Feb. 24 (HealthDay News) -- ... and the development of skin and the nervous system ... University researchers have found. , Their discovery about the ... methods of repairing damaged enamel and preventing cavities, restoring ...
... promiscuity, experts stress, , , TUESDAY, Feb. 24 (HealthDay News) -- ... have sex, but a new study provides another suggestion that ... and teenage sexual activity. , The findings indicate that ... more likely to copy or emulate what they hear," said ...
Cached Medicine News:Health News:Procter & Gamble and World Vision Equip and Empower Zimbabweans in Fight Against Cholera 2Health News:Procter & Gamble and World Vision Equip and Empower Zimbabweans in Fight Against Cholera 3Health News:NY Fashion Designer Shoshanna Creates Exclusive Spring Bag for Beauty.com 2Health News:NY Fashion Designer Shoshanna Creates Exclusive Spring Bag for Beauty.com 3Health News:Top 5 Most Annoying Dental Patient Behaviors 2Health News:Scientists Find Gene for Tooth Enamel 2Health News:'Degrading' Lyrics Linked to Teen Sex 2Health News:'Degrading' Lyrics Linked to Teen Sex 3
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
... latest and most advanced fecal occult blood ... An immunochemical FOBT (iFOBT) with high specificity ... to detect bleeding associated with more cancers ... of its superior specificity for lower GI ...
AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: